GSK to pay Tolerx $15M for study of diabetes drug

08/7/2008 | American City Business Journals

Tolerx started a late-stage clinical study of otelixizumab that involves 240 adults with new-onset Type 1 diabetes. The biopharmaceutical firm will receive $15 million in a milestone payment from partner GlaxoSmithKline for the study, which is being conducted in North America and Europe.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN